Hopt U T, Drognitz O, Neeff H
Universitätsklinikum der Albert-Ludwigs-Universität, Chirurgische Klinik, Freiburg, Abteilung Allgemein- und Viszeralchirurgie, Hugstetterstrasse 55, Freiburg, Germany.
Zentralbl Chir. 2009 Sep;134(5):425-9. doi: 10.1055/s-0029-1224612. Epub 2009 Sep 15.
Timing of surgical therapy in patients with synchronous colorectal liver metastases is becoming more complex. The standard therapy for most of the patients remains resection of the colorectal cancer first followed 6 weeks later by liver resection. Simultaneous colon and liver resection is safe and advisable in cases of minor liver resections and right-sided colon tumours. Major liver resections in combination with resection of the colorectal cancer carry the risk of increased postoperative morbidity and mortality. They should be considered for selected patients only. A pre-requisite is, in addition, special expertise of the operating surgeon in colorectal as well as in hepatobiliary surgery. If the synchronous liver metastases are near to essential anatomic structures, the liver resection should be performed before the bowel resection. The same holds if the metastases are technically resectable, but the future liver remnant seems to be too small. Using well known techniques, the future liver remnant should be increased and the liver metastases resected before treatment of the colonic primary tumour. The risk for local complications is very low when leaving the colorectal tumour in situ during treatment of liver metastases. When synchronous liver metastases are technically not resectable or carry a high risk of an R1 resection, patients should be treated first with systemic neo-adjuvant chemotherapy. If sufficient down-sizing of the metastases can be achieved, liver resection should be performed before bowel resection. A close cooperation between the oncologist and the hepatobiliary surgeon is most important, since the window for curative surgery is rather limited in these patients. In patients with resectable synchronous liver metastases, the advantage of a neoadjuvant chemotherapy has not been proven yet.
同时性结直肠癌肝转移患者手术治疗的时机正变得越来越复杂。大多数患者的标准治疗方案仍是先切除结直肠癌,6周后再进行肝切除。对于小范围肝切除和右侧结肠癌肿瘤患者,同期进行结肠和肝切除是安全且可取的。将大范围肝切除与结直肠癌切除相结合会增加术后发病率和死亡率的风险,仅应考虑特定患者。此外,手术医生必须具备结直肠以及肝胆外科的专业技能。如果同时性肝转移靠近重要解剖结构,应在肠切除之前进行肝切除。如果转移灶在技术上可切除,但未来肝残余体积似乎过小,情况也是如此。应采用已知技术增加未来肝残余体积,并在治疗结肠原发肿瘤之前切除肝转移灶。在治疗肝转移期间将结直肠癌原位保留时,局部并发症的风险非常低。如果同时性肝转移在技术上不可切除或存在高风险的R1切除,患者应首先接受全身新辅助化疗。如果能够充分缩小转移灶的大小,应在肠切除之前进行肝切除。肿瘤学家和肝胆外科医生之间的密切合作最为重要,因为这些患者的根治性手术时机相当有限。对于可切除的同时性肝转移患者,新辅助化疗的优势尚未得到证实。